Literature DB >> 20091563

Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF).

Zabeena Pandian1, Alison R McTavish, Lorna Aucott, Mark Pr Hamilton, Siladitya Bhattacharya.   

Abstract

BACKGROUND: The success of in-vitro fertilisation (IVF) depends on adequate follicle recruitment by using controlled ovarian stimulation with gonadotrophins. Failure to recruit adequate follicles is called 'poor response'. Various treatment protocols have been proposed that are targeted at this cohort of women, aiming to increase their ovarian response.
OBJECTIVES: To compare the effectiveness of different treatment interventions in women who have poor response to controlled ovarian hyperstimulation (are poor responders) in the context of IVF. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register of controlled trials (MDSG) (5/1/2009), the Cochrane Central Register of Controlled trials (CENTRAL) (4th Quarter 2008), MEDLINE (1950 to November week 3 2008), EMBASE (1980 to 2008 week 52) and The National Research Register (NRR). The citation lists of relevant publications, review articles, abstracts of scientific meetings and included studies were also searched. The authors were contacted to clarify data that were unclear from the trial reports. SELECTION CRITERIA: Only randomised controlled trials (RCTs) comparing one type of intervention versus another for controlled ovarian stimulation of poor responders to a previous IVF treatment, using a standard long protocol were included. DATA COLLECTION AND ANALYSIS: Two reviewers independently scanned the abstracts, identified relevant papers, assessed trial quality and extracted relevant data for inclusion. Validity was assessed in terms of method of randomisation, completeness of treatment cycle and co-intervention. Where possible, data were pooled for analysis. MAIN
RESULTS: The new search identified fifteen trials. Three trials were eligible for inclusion. Ten trials involving eight different comparison groups have been included. Only one trial reported live birth rates.The number of oocytes retrieved were significantly less in the conventional GnRHa long protocol compared to stop protocol and GnRH antagonist protocol.Total dose of gonadotrophins used was significantly higher in the GnRHa long protocol group compared to the Stop protocol and GnRH antagonist groups.Cancellation rates were significantly higher in the GnRHa flare up group compared to the GnRHa long protocol group.None of the studies reported a difference in the miscarriage and ectopic pregnancy rates. AUTHORS'
CONCLUSIONS: There is insufficient evidence to support the routine use of any particular intervention either for pituitary down regulation, ovarian stimulation or adjuvant therapy in the management of poor responders to controlled ovarian stimulation in IVF. More robust data from good quality RCTs with relevant outcomes are needed.

Entities:  

Mesh:

Year:  2010        PMID: 20091563     DOI: 10.1002/14651858.CD004379.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  52 in total

1.  Does the degree of hypothalamic-pituitary-ovarian recovery after oral contraceptive pills affect outcomes of IVF/ICSI cycles receiving GnRH-antagonist adjuvant therapy in women over 35 years of age?

Authors:  Carla Schmitz; Silvina Bocca; Hind Beydoun; Laurel Stadtmauer; Sergio Oehninger
Journal:  J Assist Reprod Genet       Date:  2012-06-23       Impact factor: 3.412

2.  Comparison of different ovarian hyperstimulation protocols efficacy in poor ovarian responders according to the Bologna criteria.

Authors:  Linli Hu; Zhiqin Bu; Yihong Guo; Yingchun Su; Jun Zhai; Yingpu Sun
Journal:  Int J Clin Exp Med       Date:  2014-04-15

3.  Effect of follicular flushing on reproductive outcomes in patients with poor ovarian response undergoing assisted reproductive technology.

Authors:  Anna L M Souza; Marcos Sampaio; Graciele B Noronha; Ludiana G R Coster; Roberta S G de Oliveira; Selmo Geber
Journal:  J Assist Reprod Genet       Date:  2017-07-21       Impact factor: 3.412

4.  Assisted reproductive technology: an overview of Cochrane Reviews.

Authors:  Cindy Farquhar; Jane Marjoribanks
Journal:  Cochrane Database Syst Rev       Date:  2018-08-17

5.  A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.

Authors:  Hakan Cakmak; Nam D Tran; A Musa Zamah; Marcelle I Cedars; Mitchell P Rosen
Journal:  Fertil Steril       Date:  2014-03-14       Impact factor: 7.329

6.  The carriers of the A/G-G/G allelic combination of the c.2039 A>G and c.-29 G>A FSH receptor polymorphisms retrieve the highest number of oocytes in IVF/ICSI cycles.

Authors:  Adolfo Allegra; Angelo Marino; Stefania Raimondo; Antonio Maiorana; Salvatore Gullo; Piero Scaglione; Aldo Volpes; Riccardo Alessandro
Journal:  J Assist Reprod Genet       Date:  2016-11-05       Impact factor: 3.412

7.  Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI.

Authors:  Charalampos Siristatidis; George Salamalekis; Konstantinos Dafopoulos; George Basios; Paraskevi Vogiatzi; Nikolaos Papantoniou
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

Review 8.  Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.

Authors:  Selma Mourad; Julie Brown; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2017-01-23

9.  Acupuncture for Poor Ovarian Response: A Randomized Controlled Trial.

Authors:  Jihyun Kim; Hoyoung Lee; Tae-Young Choi; Joong Il Kim; Byoung-Kab Kang; Myeong Soo Lee; Jong Kil Joo; Kyu Sup Lee; Sooseong You
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

10.  Association between GnRH Receptor Polymorphisms and Luteinizing Hormone Levels for Low Ovarian Reserve Infertile Women.

Authors:  Shun-Long Weng; Shu-Ling Tzeng; Chun-I Lee; Chung-Hsien Liu; Chun-Chia Huang; Shun-Fa Yang; Maw-Sheng Lee; Tsung-Hsien Lee
Journal:  Int J Environ Res Public Health       Date:  2021-06-30       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.